

Yohann RepessÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12039712/publications.pdf>

Version: 2024-02-01

14
papers

527
citations

933447

10
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

730
citing authors

#	ARTICLE	IF	CITATIONS
1	ABO blood group does not influence Childâ€Pugh A cirrhosis outcome: An observational studyÂfrom CIRRAL and ANRS CO12 CIRVIR cohorts. <i>Liver International</i> , 2022, 42, 1386-1400.	3.9	2
2	Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. <i>PLoS ONE</i> , 2019, 14, e0218258.	2.5	12
3	Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. <i>Haematologica</i> , 2019, 104, e369-e372.	3.5	4
4	Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi. <i>Circulation</i> , 2017, 136, 646-660.	1.6	112
5	GpIb±-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. <i>Blood</i> , 2014, 123, 3354-3363.	1.4	64
6	Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. <i>Haematologica</i> , 2013, 98, 1650-1655.	3.5	29
7	Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1172-1173.	2.9	16
8	Induction of heme oxygenase-1 in factor VIIIâ€“deficient mice reduces the immune response to therapeutic factor VIII. <i>Blood</i> , 2010, 115, 2682-2685.	1.4	28
9	Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1093-1098.	3.4	8
10	A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 37, 105-113.	6.5	24
11	The role of VWF in the immunogenicity of FVIII. <i>Thrombosis Research</i> , 2008, 122, S3-S6.	1.7	15
12	Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. <i>Haematologica</i> , 2008, 93, 83-89.	3.5	34
13	VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. <i>Blood</i> , 2007, 109, 610-612.	1.4	179
14	Von Willebrand Factor Protects Factor VIII from Endocytosis by Human Monocytesâˆ™Derived Dendritic Cells and Subsequent Presentation to Immune Effectors.. <i>Blood</i> , 2006, 108, 761-761.	1.4	0